Medindia

X

Vivakor Divisions Continue to Demonstrate Independent Growth

Wednesday, December 16, 2009 Corporate News J E 4
Advertisement


CORALVILLE, Iowa, Dec. 15 Vivakor, Inc. (OTC Bulletin Board: VIVK) Several of Vivakor's divisions have reported strong performance in 2009. Vivakor is a transdisciplinary hub of research and development with divisional spokes developing multiple products and technologies for market. Vivakor's R&D Product Pipeline strategy is anchored to the concept of licensing and strategic partnering. From idea inception, Vivakor's R&D efforts target commercialization and product-specific exit strategies to increase revenue potential from each new Vivakor technology. With a multi-million dollar purchase commitment in its nutraceutical division, new market opportunities and distribution agreements for its VivaThermic division's cryovials and continued growth in optics and MRI technology, the continued success of each of these divisions is seen as strong validation for the business model.

Executive Chairman Matt Nicosia was quoted: "Vivakor has made great strides in 2009. With the recent successes in several of our divisions, we are certain that the value proposition of our company will continue to increase. We expect continued success on several tracks and expect 2010 to be our most successful in terms of commercial success and equity value perspectives. Our greatest strength is from our diversity."

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:

Vivakor Investor Relations

c/o IME Advisors

(888) 648-8485

SOURCE Vivakor, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Access Pharmaceuticals Appoints Sales and Marketin...
S
Team Health Holdings, Inc. Prices Initial Public O...